emtricitabine; tenofovir disoproxil fumarate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806	ANDA	Camber Pharmaceuticals, Inc.	31722-560-30	30 TABLET, FILM COATED in 1 BOTTLE (31722-560-30)	2021-10-07
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806	ANDA	A-S Medication Solutions	50090-7719-1	30 TABLET, FILM COATED in 1 BOTTLE (50090-7719-1)	2021-10-07
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806	ANDA	Redpharm Drug	67296-2198-3	3 TABLET, FILM COATED in 1 BOTTLE (67296-2198-3)	2021-10-07
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806	ANDA	Redpharm Drug	67296-2198-5	5 TABLET, FILM COATED in 1 BOTTLE (67296-2198-5)	2021-10-07
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes key suppliers of emtricitabine and tenofovir disoproxil fumarate (TDF), critical active pharmaceutical ingredients (APIs) in antiretroviral therapies. Market dynamics, patent landscapes, and manufacturing capabilities of major API producers are examined to inform strategic R&D and investment decisions.

What is the Market Landscape for Emtricitabine and Tenofovir Disoproxil Fumarate APIs?

The global market for emtricitabine and tenofovir disoproxil fumarate APIs is substantial, driven by their widespread use in combination antiretroviral therapies (ART) for Human Immunodeficiency Virus (HIV) treatment and prevention (PrEP). These APIs are foundational components of highly successful fixed-dose combination drugs, including Truvada and Atripla, which have seen significant generic competition following patent expiries.

The market is characterized by a mature supply chain with established manufacturers, primarily located in Asia, particularly India and China. These regions benefit from lower manufacturing costs, skilled labor, and robust chemical synthesis infrastructure. Key market drivers include the continued prevalence of HIV globally, government initiatives for HIV treatment access, and the ongoing demand for cost-effective generic ART formulations.

The competitive landscape is influenced by regulatory requirements for API quality and Good Manufacturing Practices (GMP), as well as pricing pressures from generic drug manufacturers. The expiry of primary patents for innovator drugs has opened the market to a broader range of API suppliers, intensifying competition.

Market size estimates vary, but the demand for these APIs is in the metric ton range annually. For instance, global demand for ART, which heavily relies on these APIs, is projected to continue growing due to increased diagnosis rates and access to treatment programs.

Who are the Key Suppliers of Emtricitabine and Tenofovir Disoproxil Fumarate APIs?

Several global manufacturers are prominent suppliers of emtricitabine and tenofovir disoproxil fumarate APIs. These companies possess the necessary technical expertise, manufacturing capacity, and regulatory compliance to serve the pharmaceutical industry.

Key Emtricitabine API Suppliers:

Gilead Sciences: While Gilead is the innovator of emtricitabine, its manufacturing operations and licensed suppliers play a role in its supply chain.
Dr. Reddy's Laboratories: A major Indian pharmaceutical company with a significant API manufacturing footprint, including emtricitabine.
Laurus Labs: An Indian API manufacturer known for its expertise in antiretroviral APIs, including emtricitabine.
Mylan N.V. (now Viatris): A global pharmaceutical company that manufactures and supplies a range of APIs, including emtricitabine, particularly for its generic formulations.
Cipla Ltd.: Another prominent Indian pharmaceutical company with substantial API production capabilities, including emtricitabine.

Key Tenofovir Disoproxil Fumarate (TDF) API Suppliers:

Gilead Sciences: As the originator, Gilead maintains a strong position in TDF supply, often through its own manufacturing or contracted partners.
Dr. Reddy's Laboratories: Also a significant producer of TDF API.
Laurus Labs: Has established capabilities in TDF API synthesis.
Mylan N.V. (now Viatris): Supplies TDF API for its generic drug portfolios.
Cipla Ltd.: A substantial contributor to TDF API supply.
Hetero Drugs Ltd.: An Indian pharmaceutical company that is a large-scale producer of APIs, including TDF.

These suppliers typically operate under strict GMP guidelines and are subject to inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Their ability to consistently produce high-purity APIs in compliance with pharmacopoeial standards is critical for their market position.

What is the Patent Landscape for Emtricitabine and Tenofovir Disoproxil Fumarate?

The patent landscape for emtricitabine and tenofovir disoproxil fumarate is largely characterized by the expiry of key composition of matter and method of use patents held by the innovator companies, primarily Gilead Sciences.

Emtricitabine:

Composition of Matter Patents: The primary patents covering the emtricitabine molecule itself have expired in major markets. For example, U.S. Patent No. 6,642,271, which claims emtricitabine, expired in late 2021. Similar expiries have occurred in other key territories.
Formulation and Use Patents: While composition of matter patents have expired, specific formulations or novel uses may still be under patent protection. However, the core API is now largely off-patent.
Generic Entry: The expiry of these patents has enabled widespread generic manufacturing and market entry for emtricitabine-containing products.

Tenofovir Disoproxil Fumarate (TDF):

Composition of Matter Patents: Similar to emtricitabine, the fundamental patents for TDF have expired. For instance, U.S. Patent No. 5,977,359, covering tenofovir disoproxil, expired in 2017.
Fumarate Salt Patents: Patents covering the specific fumarate salt form of TDF have also expired in key markets, further facilitating generic production.
Formulation and Polymorph Patents: While the core molecule and its common salt form are off-patent, specific crystalline forms (polymorphs) or advanced formulations might have residual patent protection. However, these are generally less impactful on broad API market entry.
Generic Entry: TDF is widely available as a generic API and is incorporated into numerous generic fixed-dose combination antiretroviral drugs.

Tenofovir Alafenamide (TAF):

It is important to distinguish TDF from Tenofovir Alafenamide (TAF), a newer prodrug of tenofovir that Gilead developed with an improved safety profile. TAF is covered by a separate and more recent set of patents, which are still largely in force, providing market exclusivity for Gilead's TAF-containing products like Genvoya and Biktarvy. Companies seeking to enter the TAF market would face significantly different patent challenges compared to TDF.

The expiration of primary patents for both emtricitabine and TDF has fostered a highly competitive generic API market, with significant price reductions for these APIs and the finished drug products.

What are the Regulatory Requirements for API Manufacturing?

API manufacturers for emtricitabine and tenofovir disoproxil fumarate must adhere to stringent global regulatory standards to ensure product quality, safety, and efficacy.

Key Regulatory Bodies and Requirements:

Current Good Manufacturing Practices (cGMP): Manufacturers must comply with cGMP regulations set forth by major regulatory agencies. These guidelines cover all aspects of production, including facility design, equipment validation, raw material sourcing, process controls, quality control testing, documentation, and personnel training.
- FDA (U.S. Food and Drug Administration): Manufacturers supplying to the U.S. market must meet FDA cGMP requirements (21 CFR Parts 210 and 211). Facilities are subject to routine FDA inspections.
- EMA (European Medicines Agency): Manufacturers supplying to the European Union must comply with EU GMP guidelines. Compliance is often demonstrated through Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or through national competent authority inspections.
- WHO (World Health Organization): WHO GMP guidelines are often followed, particularly by manufacturers supplying to developing countries.
Pharmacopoeial Standards: APIs must meet the purity and quality specifications outlined in official pharmacopoeias.
- United States Pharmacopeia (USP): Emtricitabine and Tenofovir Disoproxil Fumarate monographs are available in the USP.
- European Pharmacopoeia (Ph. Eur.): Corresponding monographs exist in the Ph. Eur.
- Japanese Pharmacopoeia (JP): Specifications may also need to meet JP standards if supplying to Japan.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities (e.g., FDA's Type II DMF). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more drugs. This allows regulatory agencies to review the API information without disclosing proprietary details to the drug product applicant.
Quality Management Systems (QMS): A robust QMS, often based on ISO 9001 principles and adapted for pharmaceutical manufacturing, is essential. This includes change control, deviation management, CAPA (Corrective and Preventive Actions), and risk management.
Impurity Profiling and Control: Manufacturers must thoroughly identify, quantify, and control process-related impurities and degradation products to ensure API safety. This includes meeting stringent limits for genotoxic impurities.
Stability Testing: Comprehensive stability studies are required to establish the retest period or expiry date of the API under defined storage conditions.

Specific Considerations for Emtricitabine and TDF:

Chirality: Emtricitabine is a chiral molecule. Manufacturers must ensure the correct enantiomer is produced with high enantiomeric purity.
Salt Formation: TDF involves the fumarate salt. Control over the salt formation process and the crystalline form is critical for API properties and stability.
Residual Solvents: Strict limits apply to residual solvents used in the synthesis process, as per ICH Q3C guidelines.

Compliance with these regulatory requirements is non-negotiable for API suppliers and is a key differentiator in market access and customer trust.

What are the Manufacturing Challenges and Opportunities?

The manufacturing of emtricitabine and tenofovir disoproxil fumarate APIs presents both challenges and opportunities for suppliers.

Manufacturing Challenges:

Synthesis Complexity: The multi-step chemical synthesis pathways for both emtricitabine and TDF require precise control over reaction conditions, reagents, and purification processes. Achieving high yields and purity consistently can be demanding.
Cost Management: With significant generic competition, there is intense pressure to reduce manufacturing costs while maintaining quality. This requires optimization of synthetic routes, efficient use of raw materials, and lean manufacturing processes.
Regulatory Compliance: Maintaining consistent compliance with evolving cGMP standards and undergoing regular inspections by multiple global regulatory bodies requires significant investment in quality systems, infrastructure, and personnel.
Impurity Control: Rigorous control of process impurities, related substances, and potential genotoxic impurities is essential and can necessitate complex purification strategies.
Supply Chain Security: Ensuring a reliable and traceable supply of key starting materials and intermediates from qualified vendors is critical to prevent production disruptions. Geopolitical factors and logistical challenges can impact this.
Environmental, Social, and Governance (ESG) Factors: Increasing scrutiny on sustainable manufacturing practices, waste reduction, and ethical sourcing adds another layer of complexity and investment.

Manufacturing Opportunities:

Process Innovation and Optimization: Opportunities exist for developing more efficient, cost-effective, and environmentally friendly synthetic routes. This can include the use of novel catalysts, continuous manufacturing techniques, or biocatalysis.
Scale and Capacity: Manufacturers with large-scale, validated production capacities are well-positioned to meet the global demand, particularly for high-volume generic markets.
Vertical Integration: Companies that can integrate upstream (starting materials) and downstream (formulation support) capabilities can offer greater supply chain control and potential cost advantages.
Quality and Regulatory Excellence: Demonstrating superior quality and a strong regulatory track record (e.g., multiple successful FDA/EMA inspections, robust DMFs) can differentiate suppliers and secure long-term contracts with global pharmaceutical companies.
Geographic Diversification: While Asia dominates API production, opportunities may arise for manufacturers in other regions to establish or expand capabilities, potentially offering supply chain resilience or localized production advantages.
Emerging Markets Demand: Continued growth in HIV treatment programs in low- and middle-income countries sustains demand for these essential APIs. Suppliers adept at navigating these markets can capitalize on this.
Newer Tenofovir Prodrugs (TAF): While TDF is largely off-patent, the manufacturing expertise gained in TDF synthesis can be a foundation for companies looking to develop capabilities in newer tenofovir prodrugs like TAF, should patent protection expire or licensing opportunities arise.

Successful API manufacturers will focus on a combination of cost efficiency, robust quality systems, regulatory adherence, and continuous process improvement.

How Do Market Dynamics Affect API Pricing and Availability?

Market dynamics significantly influence the pricing and availability of emtricitabine and tenofovir disoproxil fumarate APIs.

Factors Affecting Pricing:

Patent Expiry and Generic Competition: The expiration of key composition of matter and salt patents for both emtricitabine and TDF has led to a highly competitive generic market. This competition has driven prices down considerably since the patent-protected innovator products were launched.
Manufacturing Costs: The cost of raw materials, energy, labor, and compliance with stringent regulatory standards are fundamental determinants of API pricing. Manufacturers with optimized processes and economies of scale generally offer lower prices.
Supply and Demand: While demand for these APIs remains consistently high due to global HIV treatment needs, the number of qualified suppliers can influence the balance. A surge in demand without a corresponding increase in supply can temporarily increase prices, though the mature nature of this market limits extreme volatility.
Regulatory Hurdles: The cost of maintaining GMP compliance, conducting rigorous quality control, and preparing comprehensive DMFs adds to the overall cost of production, which is then factored into pricing.
Geopolitical and Economic Factors: Currency fluctuations, trade policies, and global economic conditions can impact the cost of raw materials and finished APIs, as well as the profitability for suppliers.
Customer Relationships and Volume: Large-volume contracts negotiated between major generic drug manufacturers and API suppliers often result in discounted pricing.

Factors Affecting Availability:

Manufacturing Capacity: The production capacity of major API manufacturers is a primary determinant of availability. Any unexpected shutdowns, regulatory actions against a facility, or natural disasters can disrupt supply.
Supply Chain Robustness: The availability of key intermediates and starting materials is crucial. Disruptions in the supply chain for these upstream components can lead to API shortages.
Regulatory Approvals: The ability of an API supplier to have their facilities and DMFs approved by regulatory agencies in target markets directly impacts their ability to sell and, therefore, the availability of their API in those regions.
Geographic Concentration of Suppliers: A significant concentration of manufacturing in a specific region (e.g., India, China) makes the global supply chain vulnerable to regional issues like pandemics, natural disasters, or trade disputes.
Inventory Management: API manufacturers and their pharmaceutical clients maintain inventories to buffer against minor supply disruptions. However, prolonged or severe disruptions can deplete these reserves.
Quality Issues: If an API batch fails quality control testing or a manufacturing facility faces regulatory non-compliance, it can lead to the rejection of existing stock and a temporary halt in availability from that source.

In the current market for emtricitabine and TDF, API prices are generally stable but highly competitive, reflecting the mature generic status of these molecules. Availability is generally good from multiple sources, provided manufacturers maintain robust quality and regulatory standing.

Key Takeaways

Emtricitabine and Tenofovir Disoproxil Fumarate (TDF) are essential APIs for HIV antiretroviral therapies, with a mature global market dominated by Asian manufacturers.
Key suppliers include Dr. Reddy's Laboratories, Laurus Labs, Mylan (Viatris), Cipla, and Hetero Drugs, alongside originator Gilead Sciences.
Primary composition of matter and salt patents for both emtricitabine and TDF have expired in major markets, allowing for widespread generic API production.
API manufacturing is governed by strict global cGMP regulations from bodies like the FDA and EMA, requiring robust quality management systems and adherence to pharmacopoeial standards.
Manufacturing challenges include synthesis complexity, cost management, and stringent impurity control, while opportunities lie in process innovation, scale, and quality excellence.
Market dynamics, particularly patent expiries and intense generic competition, have led to competitive pricing and generally stable availability for these APIs.

Frequently Asked Questions

1. Are there any active patents that could restrict the supply of generic emtricitabine or TDF APIs?

While the primary composition of matter patents have expired, specific patents related to novel formulations, polymorphs, or advanced synthetic processes could exist. However, these are generally less impactful on broad API market entry compared to core molecule patents.

2. What is the typical lead time for ordering bulk quantities of these APIs from a supplier?

Lead times can vary depending on supplier inventory, production schedules, and order volume, but typically range from 4 to 12 weeks for bulk orders.

3. How does the quality of emtricitabine API from different suppliers typically compare?

Reputable suppliers adhering to cGMP and pharmacopoeial standards (USP, Ph. Eur.) will produce API of comparable quality. Differences may arise in impurity profiles or specific polymorphic forms, which are detailed in DMFs and Certificates of Analysis.

4. What are the main risks associated with relying on a single supplier for emtricitabine or TDF API?

Reliance on a single supplier poses risks of supply chain disruption due to manufacturing issues, regulatory actions, geopolitical events, or force majeure. Diversifying suppliers mitigates these risks.

5. How frequently do regulatory agencies like the FDA inspect API manufacturing facilities for these drugs?

FDA inspections are typically risk-based. Facilities that supply to the U.S. market can expect inspections every 2-5 years, with more frequent inspections for facilities with a history of non-compliance or those producing critical drugs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21, Part 210 and 211: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. U.S. Government Publishing Office. [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good Manufacturing Practice. [3] United States Pharmacopeia. (n.d.). USP-NF Online. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). CEP Procedure. [5] Gilead Sciences, Inc. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018). U.S. Court of Appeals for the Federal Circuit. [6] U.S. Patent No. 6,642,271. (2004). Emtricitabine. [7] U.S. Patent No. 5,977,359. (1999). Tenofovir disoproxil. [8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2016). ICH Harmonised Tripartite Guideline Q3C(R8): Impurities: Guideline for Residual Solvents.

Suppliers and packagers for generic pharmaceutical drug: emtricitabine; tenofovir disoproxil fumarate